Beta Bionics reported preliminary, unaudited net sales of at least $32.0 million for Q4 2025, marking a 56% increase from the $20.4 million recorded in Q4 2024. Growth was driven by the Durable Medical Equipment (DME) channel, which generated at least $22.3 million (up 23% year-over-year), and a 308% surge in Pharmacy Benefit Plan (PBP) channel sales to $9.7 million. These figures exceed consensus estimates, underscoring rapid traction in both traditional and pharmacy benefit distribution networks.

The company’s installed customer base rose to at least 35,000 users, up 128% from 15,298 at the end of Q4 2024. New patient starts in the quarter reached at least 5,581, a 36% increase over last year’s 4,084. Approximately 69% of new users transitioned from multiple daily injections, while a low-30s percentage of starts were reimbursed through the PBP channel. Notably, 25–30% of new patient starts were patients with type 2 diabetes, reflecting broadened adoption beyond the company’s initial type 1 diabetes focus.

Beta Bionics plans to release its audited fourth quarter and full year 2025 financial results on February 17, 2026, following market close. Management will host a conference call and webcast at 4:30 pm Eastern (1:30 pm Pacific) to review performance metrics and discuss strategic priorities. In-person investor meetings are scheduled in San Francisco from January 12–14, with registration available through the investor relations team. Executives have cautioned that the preliminary figures are subject to audit adjustments, and full financial disclosures will be provided in the Form 10-K filing.